Ozempic (Semaglutide): Weight Loss Clinics Near You

Ozempic is a branded semaglutide injection made by Novo Nordisk. In the FDA reference file, Ozempic is approved for type 2 diabetes and is not FDA-approved for weight loss, even though many patients search for it in weight-loss clinic settings.

Mechanistically, Ozempic is still semaglutide, a GLP-1 receptor agonist that helps regulate appetite, slow gastric emptying, and improve insulin sensitivity. That overlap is why Ozempic and Wegovy are so often compared.

The reference file’s main weight-loss trial data for semaglutide comes from the Wegovy program, especially the STEP 1 trial, 2021. That trial reported average body-weight loss of 14.9% over 68 weeks versus 2.4% with placebo, but it should not be described as an Ozempic weight-loss approval claim.

Per the FDA label, Ozempic starts at 0.25 mg weekly, then increases to 0.5 mg, with a labeled maximum of 2 mg weekly. Patients comparing Ozempic to Wegovy should notice that the branded products have different approved indications and different dosing ceilings.

The FDA reference lists Ozempic at roughly $900 to $1,000 per month retail without insurance.

Prices vary by pharmacy and location, and actual out-of-pocket cost depends heavily on plan coverage, indication, and pharmacy channel.

Manufacturer savings programs may be available in some cases, but patients should verify current terms and eligibility directly.

Prices vary by pharmacy, location, and clinic structure.

Ozempic and Wegovy share the same active ingredient, but they are not interchangeable from a labeling standpoint. Ozempic is FDA-approved for type 2 diabetes, while Wegovy is FDA-approved for chronic weight management.

That means a good clinic conversation usually centers on indication, dose pathway, insurance, and whether semaglutide is even the right category for the patient in the first place.